2019
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia
Bewersdorf JP, Shallis RM, Boddu PC, Wood B, Radich J, Halene S, Zeidan AM. The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia. Blood Reviews 2019, 43: 100650. PMID: 31883804, DOI: 10.1016/j.blre.2019.100650.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid leukemiaHard clinical outcomesClinical trial evidenceMeasurable residual diseaseResidual leukemic cellsRisk of relapseApprovable endpointsMRD statusDeep remissionMorphologic remissionMRD assessmentOverall survivalMRD levelsClinical outcomesDisease relapseInitial treatmentResidual diseaseTrial evidenceClinical trialsTreatment decisionsSurrogate endpointsBone marrowPreemptive interventionLeukemic cells
2017
Changes in intestinal microbiota and their effects on allogeneic stem cell transplantation
Shallis RM, Terry CM, Lim SH. Changes in intestinal microbiota and their effects on allogeneic stem cell transplantation. American Journal Of Hematology 2017, 93: 122-128. PMID: 28842931, DOI: 10.1002/ajh.24896.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantStem cell transplantCell transplantIntestinal microbiotaAllogeneic hematopoietic stem cell transplantAllogeneic stem cell transplantationHematopoietic stem cell transplantIntestinal immune toleranceStem cell transplantationClostridium difficile infectionDiverse intestinal microbiotaHuman intestinal microbiotaHost diseaseDisease relapseImmune toleranceCell transplantationDifficile infectionIntestinal microbial communitySystemic conditionsAppropriate treatmentMicrobial homeostasisTransplantPathologic statesMajor causeEarly detection